Cassell G H, Waites K B, Pate M S, Canupp K C, Duffy L B
Department of Microbiology, University of Alabama, Birmingham 35294.
Diagn Microbiol Infect Dis. 1989 Sep-Oct;12(5):433-5. doi: 10.1016/0732-8893(89)90115-6.
Lomefloxacin was found to be comparable to ciprofloxacin in its ability to inhibit the in vitro growth of Mycoplasma pneumoniae (MIC range 2-8 mcg/ml), but it was significantly less active than erythromycin. Although 30 different strains from widely differing geographic areas and isolation time periods were examined, no macrolide-resistant strains were observed.
